Imugene Ltd

IMU

Company Profile

  • Business description

    Imugene Ltd is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.

  • Contact

    4-6 Bligh Street
    Suite 12.01, Level 12
    SydneyNSW2000
    AUS

    T: +61 294230881

    https://www.imugene.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2027

    Employees

    5

Stocks News & Analysis

stocks

ASX healthcare share remains undervalued ahead of earnings

Margin recovery remains the key driver for this ASX healthcare share.
stocks

Alphabet earnings: Strong AI monetization continues to spearhead results

We maintain our fair value estimate for wide-moat Alphabet.
stocks

AMD: We’re pleased with Anthropic Partnership ahead of advancing AI event

We’re encouraged that AMD will count Anthropic as a third leading AI customer, in addition to OpenAI and Meta.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,941.5032.70-0.36%
CAC 408,326.2727.180.33%
DAX 4024,958.55195.430.79%
Dow JONES (US)51,711.65506.93-0.97%
FTSE 10010,681.3642.190.40%
HKSE24,963.23247.58-0.98%
NASDAQ25,137.69553.21-2.15%
Nikkei 22564,611.151,811.45-2.73%
NZX 50 Index13,772.2923.02-0.17%
S&P 5007,408.3090.66-1.21%
S&P/ASX 2008,772.3023.40-0.27%
SSE Composite Index3,814.2062.58-1.61%

Market Movers